Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open label phase II basket trial exploring the efficacy and safety of the combination of Niraparib and Dostarlimab in patients with DNA repair-deficient or platinum-sensitive solid tumors

Next Previous
X
Search
Trial Profile

An open label phase II basket trial exploring the efficacy and safety of the combination of Niraparib and Dostarlimab in patients with DNA repair-deficient or platinum-sensitive solid tumors

Status: Suspended
Phase of Trial: Phase II

Latest Information Update: 15 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dostarlimab (Primary) ; Niraparib (Primary)
  • Indications Adenocarcinoma; Biliary cancer; Bladder cancer; Ductal carcinoma; Gastric cancer; Head and neck cancer; Oesophageal cancer; Renal cell carcinoma; Solid tumours
  • Focus Therapeutic Use
  • Acronyms NIRADO

    • Most Recent Events

    • 25 Mar 2024 Planned End Date changed from 1 Mar 2027 to 1 Dec 2027.
    • 25 Mar 2024 Planned primary completion date changed from 1 Mar 2024 to 1 Dec 2024.
    • 25 Mar 2024 Status changed from not yet recruiting to suspended.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top